Analytics

PDMA Sample Accountability: The Rules, the Annual Reconciliation and the Data Behind It

PDMA sample accountability explained: the 21 CFR 203 records, the annual rep inventory and reconciliation, the April 1 FDA report, and how to choose a vendor.

Nov 202616 min readAnalytics

PDMA sample accountability: the short answer

PDMA sample accountability is the set of records, counts and controls that every US drug manufacturer or authorized distributor must keep for the free samples it gives to prescribers, as required by the Prescription Drug Marketing Act and its regulations in 21 CFR Part 203. In practice that means a signed written request and a signed receipt for every sample delivered, a licence check on every requesting practitioner, a complete physical inventory of every sales representative's samples at least once a year reconciled against the previous count, random and for-cause audits run by people outside the sales force, FDA notification within 5 working days of a significant loss, known theft or suspected diversion, and records kept for at least 3 years. On top of that, Section 6004 of the Affordable Care Act requires an annual report of sample requests and distributions to FDA by April 1.

The rules are not the hard part. The hard part is that the data lives in several places. Requests and signatures are captured on tablets in the CRM, shipments come from a fulfilment vendor, inventory counts may be done by a third party, licence checks run against a reference file, and the April 1 report is assembled from all of it. When those sources disagree, the annual reconciliation turns into weeks of chasing representatives for explanations, and a discrepancy nobody can explain becomes an investigation with a regulatory clock attached.

This guide covers what each section of Part 203 requires, the records a sample accountability program must be able to produce, a worked reconciliation with real arithmetic, the three ways mid-sized companies run the program, the red flags that should trigger an audit, and when you do not need to buy anything. It is written for compliance, commercial operations and sales operations leads at emerging and mid-sized pharma and biotech companies. It is not legal advice: your counsel decides how the rules apply to your program.

The PDMA sample clocks in numbers

1x/yearminimum frequency of a complete physical inventory of every representative's samples, reconciled to the prior count (21 CFR 203.31(d))
5 daysworking days to notify FDA after learning of a significant loss, known theft, falsified records or suspected diversion (21 CFR 203.37)
3 yearsminimum retention for sample distribution records from the date they were created, producible to FDA within 2 business days (21 CFR 203.60)
April 1annual deadline for the ACA Section 6004 report of sample requests and distributions, submitted to FDA through the Electronic Submissions Gateway

What does PDMA sample accountability require under 21 CFR 203?

Subpart D of 21 CFR Part 203 sets out the sample rules section by section. Here is what each one means for the data your program has to hold.

Samples by mail or common carrier (203.30). The practitioner must send a written request before delivery, and the manufacturer or distributor must verify with the appropriate state authority that the practitioner is licensed or authorized to prescribe. The request must show the practitioner's name, address, professional title and signature, their state licence or authorization number (or DEA number for a scheduled product), the drug name and strength, the quantity, the manufacturer's name and the date. The recipient signs a receipt on a form designated by the manufacturer, recording the drug, strength, quantity and delivery date, and the receipt comes back to the sender. Deliveries to a hospital or health care entity pharmacy carry extra fields for the pharmacy and the person who accepted delivery.

Samples handed over by representatives (203.31). The same request, licence check and receipt apply, with the request signed by the licensed practitioner before delivery. Section 203.31(d) then adds the annual physical inventory and a written reconciliation report, covered in detail below, and requires appropriate internal controls against error and fraud. Any discrepancy that cannot be justified must be fully investigated. Section 203.31(e) requires a list of the names and addresses of every representative who distributes samples and every site where samples are stored.

Written policies (203.34). The company must establish, maintain and follow written procedures for reconciling requests and receipts, including how it identifies patterns of nonresponse and what it does about them; for the annual inventory and reconciliation report; for a sample distribution security and audit system that includes random and for-cause audits of representatives by personnel independent of the sales force; for how representatives store samples; and for identifying and reporting significant losses and monitoring theft.

Investigation and notification (203.37). If the company has reason to believe anyone has falsified sample requests, receipts or records, or is diverting samples, it must notify FDA by telephone or in writing within 5 working days, start an investigation immediately and send a complete written report within 30 days of the first notification. The same 5-day and 30-day clocks apply to a significant loss or known theft. A representative's conviction for a sample offence must be reported within 30 days of the company learning of it, and the company must tell FDA in writing who its sample contact person is.

Lot numbers and labelling (203.38). Each sample unit and its outer container must carry a lot or control number, and distribution records must allow each unit to be traced to the licensed practitioner who received it. The label must clearly show it is a sample, for example "sample" or "not for sale".

Records (203.60). Sample distribution records must be kept for at least 3 years from creation and made available to FDA or other federal, state or local officials within 2 business days of a request. Electronic records and signatures are allowed if they meet 21 CFR Part 11, which is why signature capture in a CRM has to sit on a validated system.

The annual FDA report (ACA Section 6004). Manufacturers and authorized distributors of record must report to FDA each year, by April 1, the identity and quantity of drug samples requested, the identity and quantity distributed, and the name, address, professional designation and signature of each person who made or signed for a request. FDA's guidance on the report, issued in draft in July 2014 and still listed as a draft, routes submissions through the Electronic Submissions Gateway using an XML specification. One useful boundary: product samples intended for patient use are excluded from Sunshine Act transfer-of-value reporting, so they belong in this report, not in Sunshine Act reporting.

The records a sample accountability program must be able to produce

  • Signed requests

    One written request per delivery, signed by the licensed practitioner before the sample changes hands, with every field 203.30 or 203.31 lists.

    • Signature dated before delivery
    • Licence or DEA number present
    • Drug, strength and quantity
  • Signed receipts

    The recipient's signed receipt on the company's designated form, returned to the manufacturer and matched back to its request.

    • Quantity delivered, not requested
    • Designee signatures identified
    • Unreturned receipts chased
  • Licence verification

    Evidence that each requesting practitioner was licensed or authorized to prescribe in their state at the time of the request.

    • Checked against the state authority
    • Expired licences blocked
    • Check date stored with the request
  • Rep inventory ledger

    Every shipment received, distribution, transfer, return, destruction and reported loss for each representative, by product, strength and lot.

    • Distribution type specified
    • Lot numbers carried through
    • Storage sites listed
  • Annual counts and reconciliation

    The physical inventory record and the written reconciliation report against the previous count, with every discrepancy evaluated.

    • Previous count attached
    • Totals by product and strength
    • Investigation notes kept
  • Audit and incident file

    Random and for-cause audit results, loss and theft reports, FDA notifications with dates, and the 30-day written reports.

    • Auditor independent of sales
    • 5 working day clock evidenced
    • Sample contact person on file

A worked example: one representative's annual reconciliation

Section 203.31(d)(2) spells out what the reconciliation report must contain: the previous inventory record; every shipment received since then, with sender, date, product, strength and units; every distribution, with recipient, date, product, strength, units and the type of distribution (delivery to a practitioner, transfer to another representative, return, destruction or other disposal); every theft or significant loss the representative reported; and a summary of totals received, distributed, lost or stolen for each product and strength. The figures below are illustrative, but the arithmetic is exactly what an auditor will do.

Product X, 10 mg. Last year's count was 120 units. Since then the representative received 300 units from the fulfilment vendor. The CRM shows 340 units delivered to practitioners against signed receipts, 20 units transferred to a colleague and 10 units returned to the manufacturer. No loss was reported. Expected on hand: 120 + 300 - 340 - 20 - 10 = 50 units. The physical count finds 44. The discrepancy is 6 units.

Product Y, 25 mg. Previous count 60, received 100, delivered 150, expected 10, counted 10. No discrepancy.

Now the investigation. The representative's tablet was offline for two days in March, and four units delivered against a paper receipt were never synced to the CRM. The paper receipt is found, signed and dated before delivery, so 4 of the 6 units are justified and the ledger is corrected with a note. Two units remain unexplained. Under 203.31(d)(4) a discrepancy that cannot be justified must be fully investigated, and the company's own written definition of significant loss under 203.34 decides whether it also triggers the 5 working day FDA notification. If the investigation finds signs of falsified receipts or diversion, the notification under 203.37(a) is required regardless of how small the number is.

Two lessons come out of every example like this. First, most discrepancies are data problems, not missing drugs: unsynced transactions, transfers recorded by only one of the two representatives, or shipments booked to the wrong lot. Second, those data problems are visible months before the count if someone is looking. A monthly expected-on-hand figure per representative, built from the same sources the auditor will use, turns the annual reconciliation into a confirmation rather than a hunt. Oracle's Siebel Life Sciences guide makes the same point from the system side: a period cannot be reconciled until every non-zero difference is corrected, and reconciliations are also needed when a representative is promoted or leaves.

How to run the annual sample reconciliation without the scramble

Freeze the population

Pull the 203.31(e) list of every active representative and storage site, and agree a count window. Representatives who joined, moved territory or left during the year need their own opening or closing counts.

Build expected on hand from source

For each representative, product, strength and lot, start from the prior count and apply fulfilment shipments, CRM distributions, transfers in and out, returns, destructions and reported losses. Use the vendor's shipment file, not the CRM's copy of it.

Count independently

Run the physical inventory with staff or a vendor independent of the sales force, record counts by lot, and lock the count file before anyone compares it with expected values.

Triage every difference

Classify each discrepancy as a data timing issue, a one-sided transfer, a wrong lot or an unexplained variance. Fix the first three in the ledger with evidence, and open an investigation for the last.

Decide on notification

Apply your written definition of significant loss and the falsification and diversion test in 203.37. Where it is met, notify FDA within 5 working days and diarise the 30-day written report.

Close, file and feed April 1

Produce the written reconciliation report for each representative, file it for at least 3 years, and use the same cleaned request and distribution data to build the ACA 6004 submission due on April 1.

Drug sample accountability: outsourced service, CRM module or analytics layer

Outsourced service

Providers such as IQVIA and Knipper offer sample accountability and reconciliation as a service. IQVIA's published list covers Part 11-validated reconciliation, field inventories and closeouts across all 50 states and Puerto Rico, for-cause audits, fulfilment and PDMA consulting; Knipper says it has run sample reconciliation since 1997. This suits a company that wants independent counts and audit staff without hiring them. You still own the source data and the decisions on notification, and the provider can only reconcile what your CRM and fulfilment vendor send.

CRM sample module

Life sciences CRMs, including Oracle Siebel Life Sciences and the Veeva and Salesforce-based platforms, handle sample requests, electronic signature capture, transfers, inventory counts and period reconciliation inside the representative's app. This is where most transactions should originate. Its limit is scope: the CRM sees what representatives record, not the fulfilment vendor's shipments, the licence reference file or the audit findings, so cross-checks between them still happen somewhere else, often in spreadsheets.

Analytics layer

A monitoring layer joins CRM sample transactions, fulfilment shipments, inventory counts, licence checks and audit results on shared keys for representative, practitioner, product and lot. It calculates expected on hand every month, flags the patterns that justify a for-cause audit, tracks unreturned receipts and produces the ACA 6004 dataset as a scheduled output. It does not replace a validated system of record or independent counts; it makes both easier to run and gives compliance a view between annual cycles.

Red flags your sample data should surface before the auditor does

A representative whose expected on hand drifts away from zero variance month after month, even if each month is small
Patterns of nonresponse: practitioners or territories where signed receipts come back late or not at all, which 203.34 says your procedures must identify
Requests signed by practitioners whose licence had expired, was in a different state, or was checked after the delivery date
Sample volumes to one practitioner far above peers in the same specialty and territory, or deliveries on days with no recorded call
Transfers recorded by the sending representative with no matching receipt by the colleague who supposedly took them
Signatures captured before the request date, identical signature images across visits, or receipts signed by an unnamed designee
Lot numbers in the field that do not match what the fulfilment vendor shipped to that representative

How to choose a sample accountability vendor, and when not to buy

Whichever route you take, judge it on the data, not the demo. Ask every provider or partner these questions and get the answers in writing.

  • Where does the expected on hand figure come from? It should be built from the fulfilment vendor's shipment file and the CRM's distribution records independently, not from one system's view of both.
  • How are licence checks evidenced? Ask which state reference data is used, how often it refreshes, and whether the check date is stored against each request.
  • How is nonresponse tracked? You need a list of unreturned receipts by practitioner and representative, with ageing, because your written procedures must say how you respond.
  • Who does the counting and auditing? Part 203 requires audits by people independent of the sales force. Confirm who those people are.
  • How is the ACA 6004 file produced? Ask whether the April 1 submission comes from the same reconciled data, or from a separate extract someone rebuilds every March.
  • Can we export everything? Records must be producible to FDA within 2 business days for at least 3 years. Make sure you can get all of it out at any time, without a services fee.

The weak points to test for are mostly ordinary: receipts that were never matched back to requests, transfers recorded on one side only, licence checks run after delivery, counts done by the representative's own manager, discrepancies explained in an email rather than in the reconciliation file, and an April 1 report that does not tie to the year's distributions.

When not to buy anything. If your brands do not distribute samples, none of this applies. If you have a handful of representatives and mail-order sampling only, a disciplined request and receipt log, a licence check at each request, an annual review and counsel's sign-off may be enough, especially if your fulfilment vendor already reconciles shipments and produces the 6004 file. Likewise, if your CRM sample module and an outsourced reconciliation provider already give you clean annual results and a straightforward April 1 report, adding an analytics layer is optional. The case for it is strongest when you have a large field force, several sample products, a history of unexplained variances, or when you already run a pharma commercial data warehouse that holds the same representative, practitioner and product keys.

Where Greenwolf fits

Greenwolf builds the data and monitoring layer around a sample accountability program. We do not give legal advice, we do not count inventory or audit representatives, and we do not replace your validated CRM or reconciliation system. We join your CRM sample transactions, fulfilment vendor shipments, inventory counts, licence checks and audit findings into one sample ledger in your own warehouse, calculate expected on hand by representative, product and lot every month, flag the red flags above for your compliance team, and produce a clean dataset for the ACA 6004 submission. The results land in a pharma compliance dashboard next to speaker programme and spend monitoring, so a drifting variance is visible in June rather than at the annual count.

If your sample transactions live in Veeva, our Veeva CRM data integration work brings them into the warehouse with calls and territories. If practitioner records are the weak point, start with customer master data management, because licence checks and nonresponse tracking both depend on one clean record per prescriber. The same field data also drives field force effectiveness and speaker program analytics, and the wider picture of our pharma work is on the specialty pharmacy analytics hub. Our founder came up through pharma commercial operations consulting at ZS, so this work starts from how representatives, sample operations and compliance actually record what happens in the field.

Questions about PDMA sample accountability

How often must pharma sales representatives' samples be inventoried?
At least once a year. Under 21 CFR 203.31(d), companies that distribute samples through representatives must conduct a complete and accurate physical inventory of all samples each representative holds at least annually and reconcile it with the most recent prior inventory. Additional closeout counts are common when a representative leaves or changes role.
What must a PDMA sample reconciliation report include?
The previous inventory record, all shipments received since then, all distributions with the type of each (delivery, transfer, return, destruction or other disposal), any reported thefts or significant losses, and a summary of totals received, distributed, lost or stolen for each product and strength. Discrepancies that cannot be justified must be fully investigated.
How quickly must a lost or stolen drug sample be reported to FDA?
Within 5 working days of becoming aware of a significant loss or known theft, under 21 CFR 203.37(b). The company must also start an investigation immediately and send FDA a complete written report within 30 days of the initial notification. The same clocks apply when there is reason to believe records were falsified or samples diverted.
How long must drug sample records be kept?
At least 3 years from the date they were created, under 21 CFR 203.60. They must be available to FDA and other federal, state or local officials for review and copying within 2 business days of a request. Electronic records are allowed if they meet 21 CFR Part 11.
What is the ACA 6004 drug sample report?
Section 6004 of the Affordable Care Act requires manufacturers and authorized distributors of record to report drug sample information to FDA by April 1 each year: the identity and quantity of samples requested and distributed, and the name, address, professional designation and signature of each requester. FDA's guidance, issued in draft in July 2014, routes submissions through the Electronic Submissions Gateway.
Who can perform PDMA sample audits?
21 CFR 203.34 requires a sample distribution security and audit system that includes random and for-cause audits of sales representatives by personnel independent of the sales force. That can be an internal compliance or audit team, or an outsourced provider, but not representatives' own sales managers.
Are drug samples reported under the Sunshine Act?
Product samples intended for patient use are excluded from Open Payments transfer-of-value reporting. They are reported to FDA under ACA Section 6004 instead, and their handling is governed by the PDMA rules in 21 CFR Part 203.

Is your next sample reconciliation going to be a hunt?

Tell us where your sample requests, shipments and counts are recorded today and we will map it in a short digital audit, then show what a monthly sample accountability view would look like for your company.

Contact us

Reviewed by Team Greenwolf Tech Labs ยท

Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.

Talk to us

Is this a problem you are living with?

If any of the above sounds like your week, tell us which part. We will come back with what it would take to fix it.

  • A reply from a consultant, not a sales sequence
  • Usually within one working day
  • No obligation, and nothing to sit through

We reply from [email protected], usually within one working day. We do not add you to a mailing list.